BioSpace News Archive

Albireo Pharma, Inc. today announced the presentation of new data at the NASPGHAN Annual Meeting being held in Orlando, Florida from October 12-15, 2022.

Ceapro Inc. today announced positive results from its collaborative project led by Dr. Donna Vine, Professor at the Department of Agriculture, Food and Nutritional Science of University of Alberta.

Innovations using cord blood in cellular therapy, including traditional stem cell transplants and regenerative medicine research, will be featured during World Cord Blood Day (WCBD) 2022.

Dr. Eric Grigsby, Founder and CEO of Neurovations, announced that Neurovations Education is the recipient of a 6.9 million-dollar grant from the Helping to End Addiction Long-term Initiative®, or NIH HEAL Initiative®.

Visiox Pharma, LLC. today announced the appointment of Cynthia Matossian , M.D. as Chief Medical Officer.

CNBX Pharmaceuticals Inc. (OTC-QB: CNBX) announced today that the Company’s patent application titled “COMPOSITION AND METHOD FOR TREATING CANCER WITH CANNABINOIDS” was filed on October 12, 2022 with the US Patent and Trademark Office (USPTO) and with the Israel Patent Office under a national phase of International Patent Application.

Carmine Therapeutics (“Carmine”), an EVX founded biotech company and emerging leader in non-viral gene therapies, today announced the first Closing of its Series A financing.

Cyclacel Pharmaceuticals, Inc. today announced it will present preliminary dose escalation data from its ongoing 065-101 Phase 1/2 clinical trial of oral fadraciclib for the treatment of patients with advanced solid tumors and lymphoma during a poster presentation at the upcoming 34th EORTC-NCI-AACR (ENA) Symposium on Molecular Targets and Cancer Therapeutics, which is being held on October 26-28th, 2022, in Barcelona, Spain.

Medidata, a Dassault Systèmes company, has launched the Intelligent Trials Diversity Module to help improve the equity of clinical trials by providing site-level participant demographic data including race, sex, age, and ethnicity.

Implant Surfaces LLC and CMDC Labs have agreed to expand a joint development effort to pursue immunological and tissue integration research relating to machined and 3D-printed titanium implantable medical devices.